- Conditions
- Diabetic Retinopathy
- Interventions
- BI 764524, Sham control of BI 764524
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 13
- States / cities
- Dothan, Alabama • Beverly Hills, California • Palo Alto, California + 10 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 529–552
of 1,617
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Diabetic Macular Edema, Diabetic Retinopathy
- Interventions
- AVD-104
- Drug
- Lead sponsor
- Aviceda Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 3
- States / cities
- Erie, Pennsylvania • Dallas, Texas • Wichita Falls, Texas
- Conditions
- Choroideremia
- Interventions
- Vitamin A palmitate
- Dietary Supplement
- Lead sponsor
- Duke University
- Other
- Eligibility
- 15 Years and older · Male only
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Age Related Macular Degeneration
- Interventions
- CGC-11047
- Drug
- Lead sponsor
- Progen Pharmaceuticals
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Macular Degeneration
- Interventions
- Celecoxib (Celebrex)
- Drug
- Lead sponsor
- National Eye Institute (NEI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2006
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Retinitis Pigmentosa, Inherited Ophthalmic Diseases
- Interventions
- Not listed
- Lead sponsor
- National Eye Institute (NEI)
- NIH
- Eligibility
- 1 Day to 100 Years
- Enrollment
- 6,618 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2015
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Age Related Cognitive Decline, Age Related Macular Degeneration
- Interventions
- Walnuts, habitual diet
- Dietary Supplement · Other
- Lead sponsor
- Loma Linda University
- Other
- Eligibility
- 63 Years to 79 Years
- Enrollment
- 708 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2016
- U.S. locations
- 1
- States / cities
- Loma Linda, California
- Conditions
- Age-Related Macular Degeneration, Choroidal Neovascularization, Genetic Counseling
- Interventions
- Early disclosure, Late disclosure
- Behavioral
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Cytomegalovirus Retinitis, HIV Infections
- Interventions
- Fomivirsen sodium, Ganciclovir
- Drug
- Lead sponsor
- Ionis Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 194 participants
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 18
- States / cities
- Los Angeles, California • Pasadena, California • San Diego, California + 14 more
- Conditions
- Macular Degeneration
- Interventions
- Not listed
- Lead sponsor
- National Eye Institute (NEI)
- NIH
- Eligibility
- 50 Years and older
- Enrollment
- 477 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2003 – 2015
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Glaucoma, Retinal Disease, Healthy
- Interventions
- KOWA OCT Bi-µ, Optovue iVue 100
- Device
- Lead sponsor
- Kowa Research Institute, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018
- U.S. locations
- 1
- States / cities
- Andover, Massachusetts
- Conditions
- Age-Related Macular Degeneration
- Interventions
- DE-120, Aflibercept
- Drug
- Lead sponsor
- Santen Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 14
- States / cities
- Phoenix, Arizona • Bakersfield, California • Walnut Creek, California + 11 more
- Conditions
- Age-related Macular Degeneration, Central Retinal Vein Occlusion, Diabetic Macular Edema
- Interventions
- Xylocaine 2% Injectable Anesthetic, Proparacaine Hydrochloride 0.5% Drop, Tetravisc 0.5% Gel, Acuvail, Intra-vitreal Anti-VEGF Drug
- Procedure · Drug
- Lead sponsor
- Retina Vitreous Associates of Florida
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- Clearwater, Florida
- Conditions
- Stargardt Disease
- Interventions
- AAVB-039
- Biological
- Lead sponsor
- AAVantgarde Bio Srl
- Industry
- Eligibility
- 8 Years to 55 Years
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 8
- States / cities
- Phoenix, Arizona • Los Angeles, California • Jacksonville, Florida + 4 more
- Conditions
- Open Angle Glaucoma (OAG), NAION( Non-arteritic Anterior Ischemic Optic Neuropathy)
- Interventions
- ER-100 epigenetic therapy
- Genetic
- Lead sponsor
- Life Biosciences Inc.
- Industry
- Eligibility
- 40 Years to 85 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 4
- States / cities
- Glendale, California • Boston, Massachusetts • New York, New York + 1 more
- Conditions
- Age-Related Macular Degeneration
- Interventions
- KH631
- Drug
- Lead sponsor
- Chengdu Origen Biotechnology Co., Ltd.
- Industry
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 7
- States / cities
- Phoenix, Arizona • Lemont, Illinois • Boston, Massachusetts + 4 more
- Conditions
- Non-proliferative Diabetic Retinopathy
- Interventions
- KSI-301, Sham injection
- Drug · Other
- Lead sponsor
- Kodiak Sciences Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 253 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 46
- States / cities
- Phoenix, Arizona • Beverly Hills, California • Fullerton, California + 42 more
- Conditions
- Retinitis Pigmentosa
- Interventions
- Minocycline
- Drug
- Lead sponsor
- National Eye Institute (NEI)
- NIH
- Eligibility
- 12 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Stargardt's Disease
- Interventions
- SAR422459
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 6 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2019
- U.S. locations
- 4
- States / cities
- Miami, Florida • Iowa City, Iowa • Portland, Oregon + 1 more
- Conditions
- Wet Macular Degeneration, Macular Degeneration, Retinal Pigment Epithelial Detachment
- Interventions
- ranibizumab
- Drug
- Lead sponsor
- Anne Fung MD
- Other
- Eligibility
- 50 Years to 99 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 3
- States / cities
- San Francisco, California • Lexington, Kentucky • Nashville, Tennessee
- Conditions
- Diabetic Retinopathy (DR), Macular Edema (ME)
- Interventions
- Animated Videos
- Behavioral
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Diabetic Retinopathy, DR, Diabetic Mellitus
- Interventions
- AEYE-DS Software
- Device
- Lead sponsor
- AEYE Health Inc
- Industry
- Eligibility
- 22 Years and older
- Enrollment
- 601 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Age-related Macular Degeneration (AMD)
- Interventions
- Brolucizumab
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 9,457 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- East Hanover, New Jersey
- Conditions
- Retinopathy, Diabetic
- Interventions
- Prednisolone Acetate 1% Ophthalmic Suspension [PRED FORTE]
- Drug
- Lead sponsor
- Ophthalmic Consultants of the Capital Region
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Troy, New York